{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:13:40Z","timestamp":1759515220552,"version":"3.40.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Legionnaires\u2019 disease (LD) is typically treated with macrolides, including the azalide azithromycin, or quinolones. In 2013, guidelines for empirical treatment of community-acquired pneumonia at Christchurch Hospital, New Zealand were changed to prioritize oral azithromycin over IV clarithromycin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine whether the change in antimicrobial guidelines led to altered outcomes for patients subsequently confirmed to have LD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with confirmed LD between 2010 and 2020 were identified from clinical and laboratory data. Hospital records were used to identify mortality, ICU admission, length of hospital stay, time to clinical stability, and time to first anti-Legionella treatment. Mean differences, risk ratios (RRs) and an interrupted time series with propensity adjustment were used to compare patient outcomes before and after the guideline change.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 323 patients included: 128 before and 195 after the change. Patient outcomes generally improved after the change including: mortality within 30\u2005days (RR 0.4, 95% CI 0.2\u20130.8); ICU admission (RR 0.6, 95% CI 0.5\u20130.9); length of stay (difference \u22122.3\u2005days, 95% CI \u22124.3 to \u22120.4); and time to clinical stability (difference \u22122.4\u2005days, 95% CI \u22124.3 to \u22120.5). The interrupted time series analysis suggested improvements in patient outcomes may have occurred regardless of the guideline change.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Outcomes for patients with LD were not worsened by the change in antimicrobial guidelines and may have improved. Overall rates of mortality were low. This result was reassuring given the harm that may result from unnecessary use of IV compared with oral antimicrobial agents.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf081","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T09:18:35Z","timestamp":1742721515000},"page":"1354-1361","source":"Crossref","is-referenced-by-count":2,"title":["A retrospective observational cohort study of oral azithromycin treatment for Legionnaires\u2019 disease"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2436-4277","authenticated-orcid":false,"given":"Lorna","family":"Pairman","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Otago Christchurch , 2 Riccarton Avenue, Christchurch ,","place":["New Zealand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Tai","family":"Beh","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Te Whatu Ora Health NZ\u2014Waitaha Canterbury, Christchurch Hospital , 2 Riccarton Avenue, Christchurch ,","place":["New Zealand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Maher","sequence":"additional","affiliation":[{"name":"Department of Medicine, Te Whatu Ora Health NZ\u2014Hauora a Toi Bay of Plenty, Tauranga Hospital , 829 Cameron Road, Tauranga ,","place":["New Zealand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon J","family":"Gardiner","sequence":"additional","affiliation":[{"name":"Department of Pathology and Biomedical Science, University of Otago Christchurch , 2 Riccarton Avenue, Christchurch ,","place":["New Zealand"]},{"name":"Infection Management Service, Te Whatu Ora Health NZ\u2014Waitaha Canterbury, Christchurch Hospital , 2 Riccarton Avenue, Christchurch ,","place":["New Zealand"]},{"name":"Pharmacy Services, Te Whatu Ora Health NZ\u2014Waitaha Canterbury, Christchurch Hospital , 2 Riccarton Avenue, Christchurch ,","place":["New Zealand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago Christchurch , 2 Riccarton Avenue, Christchurch ,","place":["New Zealand"]},{"name":"Department of Clinical Pharmacology, Te Whatu Ora Health NZ\u2014Waitaha Canterbury, Christchurch Hospital , 2 Riccarton Avenue, Christchurch ,","place":["New Zealand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Williman","sequence":"additional","affiliation":[{"name":"Biostatistics and Computation Biology Unit, University of Otago Christchurch , 2 Riccarton Avenue, Christchurch ,","place":["New Zealand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen T","family":"Chambers","sequence":"additional","affiliation":[{"name":"Department of Pathology and Biomedical Science, University of Otago Christchurch , 2 Riccarton Avenue, Christchurch ,","place":["New Zealand"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"2025050205520844600_dkaf081-B1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S1473-3099(19)30113-6","article-title":"The burden of Legionnaires\u2019 disease in New Zealand (LegiNZ): a national surveillance study","volume":"19","author":"Priest","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2025050205520844600_dkaf081-B2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/thorax.58.5.377","article-title":"Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study","volume":"58","author":"Lim","year":"2003","journal-title":"Thorax"},{"article-title":"Adult Community Acquired Pneumonia","year":"2019","author":"British Thoracic Society","key":"2025050205520844600_dkaf081-B3"},{"key":"2025050205520844600_dkaf081-B4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/cid\/cit504","article-title":"Impact of routine systematic polymerase chain reaction testing on case finding for Legionnaires\u2019 disease: a pre\u2013post comparison study","volume":"57","author":"Murdoch","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025050205520844600_dkaf081-B5","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/resp.12808","article-title":"Legionnaires\u2019 disease caused by Legionella longbeachae: clinical features and outcomes of 107 cases from an endemic area","volume":"21","author":"Isenman","year":"2016","journal-title":"Respirology"},{"key":"2025050205520844600_dkaf081-B6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/jac\/41.2.289","article-title":"Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin\/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells","volume":"41","author":"Stout","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"2025050205520844600_dkaf081-B7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1128\/AAC.35.1.180","article-title":"In vitro activity of azithromycin against clinical isolates of Legionella species","volume":"35","author":"Edelstein","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205520844600_dkaf081-B8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/jac\/43.6.747","article-title":"The treatment of Legionnaires\u2019 disease","volume":"43","author":"Dedicoat","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"2025050205520844600_dkaf081-B9","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1086\/379329","article-title":"Azithromycin in the treatment of Legionella pneumonia requiring hospitalization","volume":"37","author":"Plouffe","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2025050205520844600_dkaf081-B10","doi-asserted-by":"publisher","first-page":"106481","DOI":"10.1016\/j.ijantimicag.2021.106481","article-title":"Treatment of legionellosis including a single intravenous dose of 1.5 g azithromycin: 18-year experience at a tertiary care hospital","volume":"59","author":"Karer","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2025050205520844600_dkaf081-B11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.cmi.2017.02.030","article-title":"Levofloxacin versus azithromycin for treating Legionella pneumonia: a propensity score analysis","volume":"23","author":"Garcia-Vidal","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2025050205520844600_dkaf081-B12","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1093\/cid\/civ157","article-title":"The association of antibiotic treatment regimen and hospital mortality in patients hospitalized with Legionella pneumonia","volume":"60","author":"Gershengorn","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025050205520844600_dkaf081-B13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/jac\/31.suppl_E.163","article-title":"The efficacy and tolerance of a three-day course of azithromycin in the treatment of community-acquired pneumonia","volume":"31","author":"Myburgh","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"2025050205520844600_dkaf081-B14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/00365549509047054","article-title":"Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study","volume":"27","author":"Kuzman","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"2025050205520844600_dkaf081-B15","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025050205520844600_dkaf081-B16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/clind\/16.6.741","article-title":"Legionnaires\u2019 disease","volume":"16","author":"Edelstein","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2025050205520844600_dkaf081-B17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1086\/428049","article-title":"Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides","volume":"40","author":"Garrido","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2025050205520844600_dkaf081-B18","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1086\/428059","article-title":"Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy","volume":"40","author":"Mykietiuk","year":"2005","journal-title":"Clin Infect Dis"},{"article-title":"Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate","year":"2024","author":"Medicines and Healthcare Products Regulatory Agency","key":"2025050205520844600_dkaf081-B19"},{"key":"2025050205520844600_dkaf081-B20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-200326020-00004","article-title":"Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions","volume":"26","author":"Leone","year":"2003","journal-title":"Drug Saf"},{"key":"2025050205520844600_dkaf081-B21","first-page":"22","article-title":"A persuasive approach to antimicrobial stewardship in Christchurch hospitals produced a sustained decrease in intravenous clarithromycin dosing and expenditure via a switch to azithromycin orally","volume":"133","author":"Gardiner","year":"2020","journal-title":"N Z Med J"},{"key":"2025050205520844600_dkaf081-B22","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3201\/eid2307.161429","article-title":"Risk factors for Legionella longbeachae Legionnaires\u2019 disease, New Zealand","volume":"23","author":"Kenagy","year":"2017","journal-title":"Emerg Infect Dis"},{"article-title":"Populations web tool","year":"2024","author":"Health New Zealand","key":"2025050205520844600_dkaf081-B23"},{"key":"2025050205520844600_dkaf081-B24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(14)62447-8","article-title":"Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"385","author":"Blum","year":"2015","journal-title":"Lancet"},{"key":"2025050205520844600_dkaf081-B25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"2025050205520844600_dkaf081-B26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.7275\/jjtm-r398","article-title":"A practical guide for using propensity score weighting in R","volume":"20","author":"Olmos","year":"2015","journal-title":"Pract Assess Res Eval"},{"key":"2025050205520844600_dkaf081-B27","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/cid\/ciaa441","article-title":"Are fluoroquinolones or macrolides better for treating Legionella pneumonia? A systematic review and meta-analysis","volume":"72","author":"Jasper","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025050205520844600_dkaf081-B28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jmii.2017.08.018","article-title":"Community-acquired Legionnaires\u2019 disease at a medical center in northern Taiwan","volume":"52","author":"Kao","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"2025050205520844600_dkaf081-B29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12879-016-1374-9","article-title":"Complex clinical and microbiological effects on Legionnaires\u2019 disease outcome; a retrospective cohort study","volume":"16","author":"Levcovich","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2025050205520844600_dkaf081-B30","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1093\/jac\/dku159","article-title":"Quinolones versus macrolides in the treatment of legionellosis: a systematic review and meta-analysis","volume":"69","author":"Burdet","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025050205520844600_dkaf081-B31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jiac.2020.10.002","article-title":"Meta-analysis of fluoroquinolones versus macrolides for treatment of Legionella pneumonia","volume":"27","author":"Kato","year":"2021","journal-title":"J Infect Chemother"},{"key":"2025050205520844600_dkaf081-B32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejim.2023.09.013","article-title":"Legionella pneumonia in hospitalized adults with respiratory failure: quinolones or macrolides?","volume":"120","author":"Ruiz-Spinelli","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2025050205520844600_dkaf081-B33","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/jac\/dkx484","article-title":"Antimicrobial susceptibilities of clinical Legionella longbeachae isolates","volume":"73","author":"Isenman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025050205520844600_dkaf081-B34","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s10096-024-04789-9","article-title":"Antimicrobial susceptibility testing reveals reduced susceptibility to azithromycin and other antibiotics in Legionella pneumophila serogroup 1 isolates from Portugal","volume":"43","author":"Minetti","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025050205520844600_dkaf081-B35","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/thoraxjnl-2016-208937","article-title":"Mortality reduction in adult community-acquired pneumonia in the UK (2009\u20132014): results from the British Thoracic Society audit programme","volume":"71","author":"Daniel","year":"2016","journal-title":"Thorax"},{"key":"2025050205520844600_dkaf081-B36","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1093\/jac\/dkx007","article-title":"Antimicrobial strategy for severe community-acquired Legionnaires\u2019 disease: a multicentre retrospective observational study","volume":"72","author":"Cecchini","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025050205520844600_dkaf081-B37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.medin.2012.05.010","article-title":"Community-acquired Legionella pneumonia in the intensive care unit: impact on survival of combined antibiotic therapy","volume":"37","author":"Rello","year":"2013","journal-title":"Medicina Intensiva"},{"key":"2025050205520844600_dkaf081-B38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejim.2024.07.026","article-title":"Quinolones or macrolides for adults with Legionnaires\u2019 disease and respiratory failure?","volume":"128","author":"Pairman","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2025050205520844600_dkaf081-B39","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/bmj.38334.591586.82","article-title":"Effectiveness of \u03b2 lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis","volume":"330","author":"Mills","year":"2005","journal-title":"BMJ"},{"key":"2025050205520844600_dkaf081-B40","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1136\/thoraxjnl-2015-207513","article-title":"Time to first antibiotic and mortality in adults hospitalised with community-acquired pneumonia: a matched-propensity analysis","volume":"71","author":"Daniel","year":"2016","journal-title":"Thorax"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1354\/62519841\/dkaf081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1354\/62519841\/dkaf081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:52:16Z","timestamp":1746179536000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/5\/1354\/8089974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,21]]},"published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf081","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,21]]}}}